Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study of possible anticancer drug reveals new mechanism of gene regulation

20.12.2002


Researchers at Washington University School of Medicine in St. Louis have discovered a possible new mechanism for regulating large groups of genes. While conducting yeast research on a potential new anticancer drug, the team identified a mechanism that enables the genome to silence large numbers of genes simultaneously, rather than each gene individually.



The finding emerged during research studying the molecular action of the drug rapamycin. Rapamycin currently is used to suppress the immune system following kidney transplantation, but it also is being investigated as a promising anticancer drug. Rapamycin stops tumor-cell growth through a mechanism unlike those used by other anticancer drugs. The findings are published in the December issue of Molecular Cell.

"This study shows how basic research can have a clinical impact," says study leader X. F. Steven Zheng, Ph.D., assistant professor of pathology and immunology. "It gives us insights into the molecular mechanism of rapamycin’s antitumor activity and may provide new targets for drug development."


As an immunosuppressant, rapamycin is different from other drugs. While other immunosuppressants tend to promote the growth of cancer cells, rapamycin blocks the proliferation of tumors. In addition, rapamycin blocks the development of blood vessels in tumors, a process known as angiogenesis. These features led doctors to test its use as an anticancer drug.

"For a single drug to block both tumor proliferation and angiogenesis is unique," says Zheng, who is an investigator with the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Test-tube experiments done by others showed that rapamycin binds to a large, previously unknown cell protein known as target of rapamycin (TOR). TOR is found in organisms from yeast to humans, suggesting that it may serve an essential purpose in cells.

Zheng and colleagues used rapamycin to inactivate TOR, enabling them to examine both TOR’s function in the cell and how rapamycin works.

The researchers identified about 300 yeast genes involved in TOR-related activities. The product of one of these genes, a protein known as silent information regulator 3 (Sir3), normally clings to a battery of genes responsible for a stress protein, thereby keeping the genes inactive and silent. Stress proteins are molecules produced by cells during adverse growing conditions.

But the researchers found that when rapamycin inactivates TOR, Sir3 molecules detach from the line of stress-protein genes, triggering a stress response: The cells begin producing stress proteins, their walls thicken and they stop proliferating.

"This surprised us," Zheng says. "TOR was not known to be directly involved in stress control. Also, this means of silencing many genes simultaneously suggests a new type of gene regulation." Usually, genes are turned on or off individually by proteins targeted to specific genes, he says.

Furthermore, the investigators found that when rapamycin inactivates TOR, it also shuts down nutrient processing pathways, preventing yeast cells from using glucose to produce energy and amino acids to make new proteins.

Overall, the researchers conclude that when rapamycin inhibits TOR, it triggers a variety of responses, including stress and starvation responses. Together, these actions probably cause the cells to stop proliferating.

These insights into rapamycin’s action must now be verified in human cells.


Ai W, Bertram PG, Tsang CK, Chan T-F, Zheng XFS. Regulation of subtelomeric silencing during stress response. Molecular Cell, December 2002.

Funding from the National Institutes of Health supported this research.

Darrell E. Ward | EurekAlert!
Further information:
http://medinfo.wustl.edu/

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>